Molecular imaging of c-Met tyrosine kinase activity

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The hepatocyte growth factor/scatter factor (HGF/SF) and its receptor c-Met signaling pathway regulates critical cellular functions.
• Dysregulation of HGF/c-Met signaling is linked to cancer progression, metastasis, and treatment resistance.
• Real-time monitoring of c-Met activity is crucial for understanding its role in disease and developing targeted therapies.

Purpose of the Study:

• To develop a genetically engineered bioluminescence reporter system to quantitatively and dynamically measure c-Met tyrosine kinase activity in living cells and animals.
• To utilize this reporter to investigate the pharmacodynamics and pharmacokinetics of agents targeting the HGF/c-Met pathway.
• To validate c-Met as a therapeutic target in human glioblastoma models.

Main Methods:

• Development of a genetically engineered reporter system where bioluminescence serves as a surrogate for c-Met kinase activity.
• Monitoring c-Met kinase activity in cultured cells and U-87 MG tumor xenografts in response to pathway modulation.
• Administering c-Met inhibitors and HGF neutralizing antibodies to tumor-bearing animals to assess reporter response and tumor growth.

Main Results:

• The bioluminescence reporter successfully monitored c-Met kinase activity quantitatively and dynamically in real-time.
• Treatment with a c-Met inhibitor and HGF neutralizing antibody dose-dependently increased reporter activity.
• These treatments also led to significant regression of U-87 MG tumor xenografts.

Conclusions:

• The developed bioluminescence reporter is a valuable tool for real-time assessment of c-Met signaling activity.
• The findings provide insights into the pharmacokinetics and pharmacodynamics of c-Met targeting agents.
• c-Met is validated as a promising therapeutic target for human glioblastoma.